[New horizons of next generation chemotherapy for mycobacteriosis].
Stop TB Partnership (WHO) reported "Global TB Research and Development Projects" on the basis of the annual survey (October 2007): Basic Research: 9 projects, Drug Discovery: 32 projects, Preclinical: 8 projects, Clinical Testing: 13 projects are in proceeding. Among them, promising 7 of the new Anti-TB drug candidates: Nitroimidazopyran PA-824, Moxifloxacin MFLX, Gatifloxacin GFLX, Diaryl-quinoline TMC-207/R207910, Nitroimidazo-oxazole OPC-67683, Pyrrole LL-3858 and Diamine SQ-109 are in progress in clinical trial Phase I-III. In 2006, Working Group on New TB Drugs (WGND)/Stop TB Partnership and Global Alliance for TB Drug Development (GATB/TB Alliance) target: by 2010, 1-2 new drugs will be registered for TB; by 2015, 7 new drugs registered for TB indication, and treatment will be shortened regimens of 3-4 months with affordable and highly effective drugs.